Hematology

The company-sponsored phase 1/2 study evaluates a cryopreserved, readily available formulation for the treatment of follicular and diffuse large B cell lymphomas.

Topline results from the KarMMa-3 trial show that idecabtagene vicleucel significantly improves progression-free survival vs standard regimens.

Based on overall response rate, acalabrutinib in tablet form is now FDA approved for all approved indications, enabling co-administration alongside a proton pump inhibitor.

If approved the drug will be the first allogeneic advanced stem cell therapy donor source for patients with blood cancers.

Expanded indication for Rebinyn could allow patients with hemophilia B to participate in physical and social activities.

Fondaparinux sodium (Arixtra) is indicated for prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery.

Pirtobrutinib is under investigation in clinical trials in patients with CLL/small lymphocytic lymphoma, mantle cell lymphoma, and non-Hodgkin lymphoma.

Data from Roche’s phase 3 HAVEN 6 study show clinically meaningful bleed control, with no new safety signals observed.

Experts discuss the pros and cons of using oral azacytidine to treat patients with acute myeloid leukemia.

Experts discuss tools and trainings that health care institutions have established during the pandemic to support hematology-oncology pharmacists who are struggling with wellness and mental health challenges.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss research conducted looking to assess the hematology-oncology pharmacist “great migration” from the field.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss the underlying causes of the hematology-oncology pharmacist great migration from the field.

Analysis results expand understanding of the impact of the company’s medicines in early stages with the goal or providing patients with durable and robust outcomes from their first treatment.

Andrea Iannucci, PharmD, BCOP, member of the Board of Directors of the Hematology/Oncology Pharmacy Association (HOPA), discusses how HOPA works within and its impact on hematology/oncology pharmacy practice management.

Two medical professionals reveal what factors into intensive chemotherapy consideration and common toxicities found when undergoing treatment.

Cole McCoy, PharmD, shares recent changes in the AML treatment landscape, including updates to the NCCN guidelines.

The treatment landscape for relapsed/refractory MZL and follicular lymphoma (FL) is shifting from intravenous chemotherapy and monoclonal antibodies to oral oncolytic therapy or CD19-directed chimeric antigen receptor (CAR) T-cell therapy.

A patient with CLL relies on his pharmacy team for support.

The role of the pharmacist in sickle cell disease management revolves around appropriate pain management.

The drug is being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant.

Cole McCoy, PharmD, and James McCloskey, MD, explain common treatment goals, cytogenetic tests, and considerations that factor into choosing individualized treatment for patients with AML.

James McCloskey, MD, and Danielle Marcotulli, APN, RN, MSN, FNP-BC, AOCNP give a brief synopsis of AML, including its definition, the different types of the condition, and a typical patient’s journey.

Results from a phase 3b study showed that venetoclax combined with azacitidine or decitabine can safely be initiated in a US community-based outpatient setting.

Ginna Laport, MD, discussed the growing body of research surrounding venetoclax.

Efanesoctocog alfa is a novel and investigational recombinant factor VIII therapy that is designed to extend protection from bleeding with a once-weekly prophylactic dosing.

AstraZeneca trial results shows 90% of patients with chronic lymphocytic leukemia surviving for 5 years.

Overall outcomes were consistent with axicabtagene ciloleucel in the real-world setting, regardless of race or ethnicity, in adults with relapsed or refractory large B-cell lymphoma.

Brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine shows improved overall survival compared with standard chemotherapy in patients with previously untreated, advanced stage classical Hodgkin lymphoma.

The FDA approved decitabine/cedazuridine in 2020 for treatment of adults with myelodysplastic syndromes.

The safety profile of valoctocogene roxaparvovec in the phase 1/2 study was consistent with previously reported data, with no delayed-onset treatment-related adverse events (AEs).